$Affimed NV (AFMD.US)$ Affimed Announces Updated Phase 1/2 D...
$Affimed NV(AFMD.US$ Affimed Announces Updated Phase 1/2 Data from Acimtamig in Combination with Allogeneic NK in Hodgkin Lymphoma Patients Who Failed Prior Chemotherapy and Are Double-Refractory to Brentuximab Vedotin (BV) and Checkpoint Inhibitors (CPIs)
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
I’m instinct based traders , I hate reading charts !
My prediction is magic!
6118Followers
135Following
186KVisitors
Follow
Revelation 6 : New name!!!